A good prognosis of endocrine-dependent tumors among residual invasive cancer after anti-HER2 therapy: CALGB 40601 (Alliance) and validation studies
- Citation:
- Cancer Res vol 81 (4 Supplement) PS10-02
- Meeting Instance:
- SABCS 2020
- Year:
- 2020
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- None
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- Pharmas:
- GSK
- Grants:
- U10CA180821, U10CA180882, U24CA196171, U10CA180888, U10CA180818, U10CA180801, P50-CA58223-09A1, R01-CA195740, R01CA229409, P30 CA008748
- Corr. Author:
- Authors:
- Sung Gwe Ahn Aranzazu Fernandez-Martinez Aleix Prat Soong June Bae Núria Chic Fara Brasó-Maristany Benedetta Conte Seho Park Valentina Guarneri Maria Vittoria Dieci Gaia Griguolo PierFranco Conte Joon Jeong Lisa A Carey Charles M. Perou
- Networks:
- LAPS-NC007
- Study
- CALGB-40601
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: